INT84430

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1999
Last Reported 2010
Negated 0
Speculated 1
Reported most in Abstract
Documents 22
Total Number 24
Disease Relevance 10.33
Pain Relevance 3.95

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Smpd1) hydrolase activity, acting on glycosyl bonds (Smpd1) lysosome (Smpd1)
Anatomy Link Frequency
lung 2
histiocytes 1
liver 1
brainstem 1
fibroblast 1
Smpd1 (Mus musculus)
Pain Link Frequency Relevance Heat
Paracetamol 12 99.00 Very High Very High Very High
fibrosis 40 98.60 Very High Very High Very High
Intracerebroventricular 4 97.36 Very High Very High Very High
allodynia 4 96.36 Very High Very High Very High
backache 2 91.52 High High
Inflammation 10 89.96 High High
cytokine 11 89.56 High High
abdominal pain 1 87.68 High High
Pain 2 86.96 High High
Inflammatory response 1 86.20 High High
Disease Link Frequency Relevance Heat
Pick Disease Of The Brain 33 99.72 Very High Very High Very High
Injury 4 99.42 Very High Very High Very High
Pulmonary Disease 7 99.12 Very High Very High Very High
Disease 222 98.88 Very High Very High Very High
Cystic Fibrosis 40 98.60 Very High Very High Very High
Hemolysis 2 98.56 Very High Very High Very High
Anaerobic Bacterial Infections 10 98.52 Very High Very High Very High
Neuropathic Pain 4 96.36 Very High Very High Very High
Immunization 2 95.60 Very High Very High Very High
Lysosome Storage Disease 5 95.28 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
D609 injection also resulted in significantly reduced ASMase activity in the brainstem, thalamus, and somatosensory cortex 3 days after injection, compared to controls.
Negative_regulation (reduced) of ASMase in thalamus
1) Confidence 0.59 Published 2009 Journal J Orofac Pain Section Body Doc Link 19492541 Disease Relevance 0.06 Pain Relevance 0
Genetic or systemic inhibition of the acid sphingomyelinase (Asm) is not feasible for treatment of patients or might cause adverse effects.
Negative_regulation (inhibition) of acid sphingomyelinase
2) Confidence 0.59 Published 2010 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 19635928 Disease Relevance 0.66 Pain Relevance 0.28
Genetic or systemic inhibition of the acid sphingomyelinase (Asm) is not feasible for treatment of patients or might cause adverse effects.
Negative_regulation (inhibition) of Asm
3) Confidence 0.59 Published 2010 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 19635928 Disease Relevance 0.67 Pain Relevance 0.28
The aim of the present investigation was to develop a structure-property-activity relation (SPAR) model in order to specify the structural and physicochemical characteristics of probes capable of functionally inhibiting ASM.
Negative_regulation (inhibiting) of ASM
4) Confidence 0.50 Published 2008 Journal J. Med. Chem. Section Abstract Doc Link 18027916 Disease Relevance 0 Pain Relevance 0.08
High p K a and high log P values are necessary but not sufficient preconditions for functional inhibition of ASM.
Negative_regulation (inhibition) of ASM
5) Confidence 0.50 Published 2008 Journal J. Med. Chem. Section Abstract Doc Link 18027916 Disease Relevance 0 Pain Relevance 0.10
The experimental data supported the requirement of an additional factor, which is necessary for functional inhibition of ASM.
Negative_regulation (inhibition) of ASM
6) Confidence 0.50 Published 2008 Journal J. Med. Chem. Section Abstract Doc Link 18027916 Disease Relevance 0 Pain Relevance 0.11
AIMS: To evaluate possible effects of the intracerebroventricular (icv) injection of either O-Tricyclo [5.2.1.0(2,6)] dec-9-yl dithiocarbonate potassium salt (D609), a potent antioxidant and inhibitor of phosphatidylcholine specific phospholipase C (PtdCho-PLC) and acid sphingomyelinase (ASMase), or the spin trap/free radical scavenger N-tert-Butyl-alpha-phenylnitrone (PBN), on mechanical allodynia induced by facial carrageenan injection in mice.
Negative_regulation (inhibitor) of ASMase associated with allodynia and intracerebroventricular
7) Confidence 0.43 Published 2009 Journal J Orofac Pain Section Abstract Doc Link 19492541 Disease Relevance 0.17 Pain Relevance 0.22
These findings employing several structurally different Asm inhibitors identify Asm as primary target in the lung to reduce ceramide concentrations.
Negative_regulation (inhibitors) of Asm in lung
8) Confidence 0.43 Published 2010 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 19635928 Disease Relevance 0.77 Pain Relevance 0.51
AIMS: To evaluate possible effects of the intracerebroventricular (icv) injection of either O-Tricyclo [5.2.1.0(2,6)] dec-9-yl dithiocarbonate potassium salt (D609), a potent antioxidant and inhibitor of phosphatidylcholine specific phospholipase C (PtdCho-PLC) and acid sphingomyelinase (ASMase), or the spin trap/free radical scavenger N-tert-Butyl-alpha-phenylnitrone (PBN), on mechanical allodynia induced by facial carrageenan injection in mice.
Negative_regulation (inhibitor) of sphingomyelinase associated with allodynia and intracerebroventricular
9) Confidence 0.38 Published 2009 Journal J Orofac Pain Section Abstract Doc Link 19492541 Disease Relevance 0.17 Pain Relevance 0.22
Inhaling an Asm inhibitor may be a beneficial treatment for CF, with minimal adverse systemic effects.
Negative_regulation (inhibitor) of Asm associated with fibrosis
10) Confidence 0.38 Published 2010 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 19635928 Disease Relevance 0.79 Pain Relevance 0.47
We tested whether inhalation of different acid sphingomyelinase inhibitors does reduce Asm activity and ceramide accumulation in lungs of CF mice.
Spec (whether) Negative_regulation (reduce) of Asm in lungs associated with fibrosis
11) Confidence 0.37 Published 2010 Journal Am. J. Respir. Cell Mol. Biol. Section Abstract Doc Link 19635928 Disease Relevance 0.73 Pain Relevance 0.32
Some organic weak bases induce a detachment from inner lysosomal membranes and subsequent inactivation of acid sphingomyelinase (ASM) and thus work as functional ASM inhibitors.
Negative_regulation (inactivation) of ASM
12) Confidence 0.37 Published 2008 Journal J. Med. Chem. Section Abstract Doc Link 18027916 Disease Relevance 0 Pain Relevance 0
From a practical standpoint, no patient should today be longer qualified of suffering from "Niemann-Pick disease" without specification of the subgroup, either acid sphingomyelinase deficiency or type C.


Negative_regulation (deficiency) of acid sphingomyelinase associated with pick disease of the brain
13) Confidence 0.35 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2902432 Disease Relevance 0.74 Pain Relevance 0
Enzymatic analysis of a fibroblast culture confirmed the diagnosis of Niemann-Pick disease type B, with reduced activity of acid sphingomyelinase.
Negative_regulation (reduced) of sphingomyelinase in fibroblast associated with pick disease of the brain
14) Confidence 0.32 Published 1999 Journal Schweiz Med Wochenschr Section Abstract Doc Link 10515006 Disease Relevance 0.98 Pain Relevance 0.09
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Negative_regulation (inhibitors) of sphingomyelinase
15) Confidence 0.32 Published 2008 Journal J. Med. Chem. Section Title Doc Link 18027916 Disease Relevance 0 Pain Relevance 0.09
Some organic weak bases induce a detachment from inner lysosomal membranes and subsequent inactivation of acid sphingomyelinase (ASM) and thus work as functional ASM inhibitors.
Negative_regulation (inhibitors) of ASM
16) Confidence 0.32 Published 2008 Journal J. Med. Chem. Section Abstract Doc Link 18027916 Disease Relevance 0 Pain Relevance 0
Some organic weak bases induce a detachment from inner lysosomal membranes and subsequent inactivation of acid sphingomyelinase (ASM) and thus work as functional ASM inhibitors.
Negative_regulation (inactivation) of sphingomyelinase
17) Confidence 0.32 Published 2008 Journal J. Med. Chem. Section Abstract Doc Link 18027916 Disease Relevance 0 Pain Relevance 0
In 1966, Brady and associates [3] demonstrated a severe deficiency in sphingomyelinase activity in tissues from patients with type A, a finding soon extended to type B, but not to types C and D, indicating that the two latter types constituted separate entities.
Negative_regulation (deficiency) of sphingomyelinase
18) Confidence 0.31 Published 2010 Journal Orphanet J Rare Dis Section Body Doc Link PMC2902432 Disease Relevance 0.29 Pain Relevance 0
The toxin possesses phospholipase C (PLC), sphingomyelinase (SMase) and biological activities causing hemolysis, lethality and dermonecrosis.
Negative_regulation (possesses) of SMase associated with hemolysis
19) Confidence 0.28 Published 2004 Journal J. Biochem. Section Abstract Doc Link 15632295 Disease Relevance 1.13 Pain Relevance 0.09
The toxin possesses phospholipase C (PLC), sphingomyelinase (SMase) and biological activities causing hemolysis, lethality and dermonecrosis.
Negative_regulation (possesses) of sphingomyelinase associated with hemolysis
20) Confidence 0.25 Published 2004 Journal J. Biochem. Section Abstract Doc Link 15632295 Disease Relevance 1.08 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox